Croda’s Classic Return: Innovation and Beauty Actives Drive a Rare Profit-Ahead-of-Sales Half
Beauty Actives surge 27%, Volufiline goes viral, and Pharma rebalancing plus transformation savings underpin an unchanged full-year outlook.
CRDA.L · Earnings Call · 2026-07-28
The shape of the half
Croda’s first half results, reported on 28 July, had a distinctly familiar ring to them—and that is exactly the point. As Chief Executive Steve Foots put it, “Our growth is classic Croda, profits growing ahead of sales and sales growing ahead of volume.” The numbers bore that out: sales rose 5% in constant currency to £881 million, adjusted operating profit grew 7% to £156 million, and EPS climbed 9% to 78p. Margin expanded 50 basis points to 17.7% despite a modest volume increase of just 1%. The acceleration was visible in the second quarter, with growth jumping to 9% from 1% in Q1, driven by Consumer Care and a standout performance in Beauty Actives, which grew 27%. The market has been watching whether Croda can genuinely re-rate after a multi-year margin slide. The first half suggests the turnaround is sticking: the company reaffirmed its full-year guidance of 3–6% organic sales growth and further margin expansion, and management pointed to a strong exit rate as the basis for confidence. Crucially, much of the improvement is self-help. Transformation delivered £18 million of savings in the half, bringing cumulative benefits to £46 million, and the program is clearly on track—headcount is down, the portfolio is being simplified (SKU rationalization is already 30% complete), and new shared-service centers are reducing overheads.Beauty in the spotlight: Volufiline and the innovation flywheel
The most striking development is the commercial traction of Volufiline, a skin-plumping active that has become a viral hit on TikTok. “If you tap Volufiline into your search engines, you’ll see a lot of hits and a lot of exposure,” Foots noted in Q&A. The ingredient, repositioned as a “facial filler in a bottle,” is now being featured by customers like Estée Lauder’s The Ordinary and Korean beauty brands, with customer requests to use Croda’s trademark rising threefold over the past year. This is not a one-off: Volufiline exemplifies a broader shift in Croda’s innovation approach—leveraging existing ingredients for new applications, accelerating time-to-market, and increasingly co-creating with customers. The Beauty Actives franchise, which includes ceramides, peptides, and biotech actives, has now posted two consecutive quarters of strong growth, and management expects “healthy growth to continue, driven by innovation.” The renewed focus on innovation is also visible in new product development: NPP (new and protected products) is growing faster than total sales. The commissioning of new sites in India (Dahej) and China (Guangzhou) during the half brings capacity closer to the fastest-growing customer base, directly supporting the internationalization of Beauty Actives. This is a deliberate strategic pivot from the cost-cutting narrative of the past two years toward an innovation-led growth story.Pharma rebalancing and transformation: the other half of the equation
While Beauty steals the headlines, the pharma business is quietly becoming a more balanced engine. Pharma Solutions, the smaller but higher-margin project-driven unit, saw softness in H1 due to phasing, but the order book suggests a solid second half. CFO Stephen Oxley explained, “the order book in Pharma Solutions is slightly different to us because it’s project-based… they’re in a bit more in the longer term in the order book than the rest of the sort of order intake.” Meanwhile, Pharma Ingredients—the other 70%—grew 7%, with high-purity excipients leading the way. Management is targeting new applications for lipids in generics and expanding the adjuvant portfolio, including biotech-derived squalene. Transformation remains the unsung hero. The program is delivering cost savings ahead of plan, and these are structural, not one-off. In February, the CFO had said, “the business transformation benefits are structural, right? So that GBP 100 million of savings continues beyond 2028.” That conviction is now bearing fruit. The company also expects working capital improvements to add to free cash flow in H2, having already lifted FCF to £38 million from £28 million a year ago.You're seeing innovation increasing, not just at our customers, but with ourselves as well, which is really driving the encouraging results. Transformation benefits are building.